CoronaVac is able to raise antibodies against covid-19 for one year
The study was conducted on 150 volunteers in China over time, to measure levels of antibodies in the blood
The study was published in preprint by the scientific journal scalpel
One study, still in pre-print stage, published by the scientific journal scalpel, indicates that a CoronaVac, a vaccine against covid-19 produced by SinoVac in partnership with Instituto Butantan, able to produce antibodies against the disease for a year.
The survey, which needs peer review, was given by the Beijing Municipal Science and Technology Commission. 150 people took part in the study, ranging in age from 18 to 59. Among them, 136 people received two doses of CoronaVac, 14 days apart.
Blood samples were collected from participants one month before vaccination, three months, six months and 12 months after receiving the vaccination. The scientists measured both the humoral response, that is, that derived from antibodies, and the cellular response, which concerns T lymphocytes.
In the first month after full immunization, antibody indices rose rapidly. The antibody-bound seropositivity rate was 99% and the neutralizing antibody seroconversion rate was 50%.
Between the third and twelfth month with full immunization, there was a slight decrease in neutralizing and binding antibodies over time. However, a year later, it was possible to detect antibodies in volunteers.